Medicine and Dentistry
Patient
100%
Non Small Cell Lung Cancer
56%
Therapeutic Procedure
35%
Lung Cancer
35%
Cells
29%
Overall Survival
24%
Epidermal Growth Factor Receptor
24%
Progression Free Survival
19%
Combination Therapy
18%
Inpatient
18%
Neoplasm
17%
Programmed Cell Death
14%
Pemetrexed
14%
Carboplatin
13%
Chemotherapy
13%
Analysis
11%
Survival
11%
Paclitaxel
11%
Diseases
10%
Toxicity
10%
Platinum
10%
Immune Checkpoint Inhibitor
10%
Epidermal Growth Factor Receptor
10%
Gefitinib
9%
Ligand
9%
Small Cell Lung Cancer
9%
Bevacizumab
8%
Cisplatin
8%
Specimen
7%
Hazard Ratio
7%
Radiation Therapy
7%
Receptor Gene
7%
Osimertinib
7%
Anaplastic Lymphoma Kinase
6%
Idiopathic Pulmonary Fibrosis
6%
Plasma
6%
Arm
6%
Epidermal Growth Factor Receptor Kinase Inhibitor
6%
Lung Adenocarcinoma
5%
Atezolizumab
5%
Non-Small Cell Lung Cancer
5%
Nivolumab
5%
Diagnosis
5%
Adverse Event
5%
Docetaxel
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
81%
Epidermal Growth Factor Receptor
37%
Chemotherapy
31%
Lung Cancer
28%
Progression Free Survival
26%
Overall Survival
25%
Carboplatin
24%
Gefitinib
21%
Paclitaxel
21%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Toxicity
20%
Erlotinib
16%
Neoplasm
16%
Osimertinib
15%
Platinum
14%
Pemetrexed
14%
Adverse Event
13%
Docetaxel
12%
Survival
12%
Diseases
12%
Afatinib
11%
Cisplatin
11%
Bevacizumab
10%
Anaplastic Lymphoma Kinase
9%
Protein Tyrosine Kinase Inhibitor
9%
Small Cell Lung Cancer
9%
Pharmacokinetics
8%
Drug
8%
Clinical Trial
8%
Ligand
8%
Nivolumab
7%
Disease Exacerbation
6%
Crizotinib
6%
Combination Therapy
6%
Durvalumab
6%
Echinoderm
5%
Microtubule Associated Protein
5%
Survivin
5%
Malignant Neoplasm
5%
Stomach Cancer
5%
Biological Marker
5%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
32%
Mutation
19%
Cancer Cell
12%
Gefitinib
8%
Anaplastic Lymphoma Kinase
7%
CD44
7%
Apoptosis
6%
Receptor Tyrosine Kinase Inhibitors
6%
Protein
5%
Overall Survival
5%
Sample
5%
Receptor Gene
5%
Progression Free Survival
5%
